Elderly patients with hormone receptor‑positive HER2‑negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Helena Pla Juher; Gemma Viñas; Roser Fort Culillas; Sonia del Barco Berrón; Eudald Felip; Mireia Margelí Vila; Beatriz Cirauqui Cirauqui; Vanessa Quiroga; Anna M. Esteve; Verónica Obadia; Sonia Pernas Simon; Agostina Stradella; Juan Miguel Gil Gil; Sabela Recalde; Nuria Sabaté; Eduard Fort Casamartina; Clara Lezcano Rubio

Ayuda

Elderly patients with hormone receptor‑positive HER2‑negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Helena Pla ^[1] ; Gemma Viñas ^[1] ; Roser Fort Culillas ^[1] ; Sonia Del Barco ^[1] ; Eudald Felip ^[3] ; Mireia Margelí ^[3] ; Beatriz Cirauqui ^[3] ; Vanesa Quiroga ^[3] ; Anna Esteve ^[3] ; Verónica Obadia ^[2] ; Sonia Pernas ^[2] ; Agostina Stradella ^[2] ; Miguel Gil Gil ^[2] ; Sabela Recalde ^[2] ; Nuria Sabaté ^[1] ; Eduard Fort ^[1] ; Clara Lezcano ^[1]
1. [1] Institute Catalá Oncología
  
  Institute Catalá Oncología
  
  Barcelona, España
2. [2] Universitat de Barcelona
  
  Universitat de Barcelona
  
  Barcelona, España
3. [3] Department of Medical Oncology-Breast Cancer Unit, Institut Català d’Oncologia (ICO)-H. U. Germans Trias i Pujol (HUGTiP), Badalona Applied Research Group in Oncology (B-ARGO), Badalona, Spain
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 7, 2024, págs. 1748-1758
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Introduction Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is a signifcant lack of data regarding the efcacy and safety of these treatments in elderly patients. We present the results of a real-world data (RWD) cohort stratifed by age at treatment initiation (≥70 years compared to patients<70 years).
  
  Methods Clinico-pathological data of HR+HER2- MBC patients who were candidates for CDK4/6i therapy between January 2017 and December 2020 at the Institut Català d'Oncologia (Spain) were retrospectively collected. The primary goal was to assess Progression-Free Survival (PFS), Overall Survival (OS), and safety outcomes within this patient population.
  
  Results A total of 274 patients with MBC who received CDK4/6i treatment were included in the study. Among them, 84 patients (30.8%) were aged≥70 years, with a mean age of 75, while 190 patients (69.2%) were under the age of 70, with a mean age of 55.7 years. The most frequently observed grade 3–4 toxicity was neutropenia, with similar rates in both the<70 group (43.9%) and the≥70 group (47.9%) (p=0.728). The median Progression-Free Survival (mPFS) for the frst-line CDK4/6i treatment was 22 months (95% CI, 15.4–39.8) in the<70 group and 20.8 months (95% CI 11.2–NR) in the≥70 group (p=0.67). Similarly, the median PFS for the second-line CDK4/6i treatment was 10.4 months (95% CI, 7.4–15.1) and 7.1 months (95% CI 4.4–21.3) (p=0.79), respectively. Median overall survival (mOS) was not reached either for the first- and second-line treatment.
  
  Conclusions Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.